Higher cecal intubation rates linked to fewer post-colonoscopy cancer deaths
-
July 15
Austrian screening data suggest a cecal intubation rate above 95% may be an appropriate quality target for screening colonoscopy.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Higher cecal intubation rates linked to fewer post-colonoscopy cancer deaths
-
by Meg Barbor
Austrian screening data suggest a cecal intubation rate above 95% may be an appropriate quality target for screening colonoscopy.
Four-week pancreatic stent interval reduces repeat endoscopies, trial finds
-
by Doug Brunk
In a nine-center Korean randomized trial, waiting four weeks instead of two to assess prophylactic pancreatic duct stents cut endoscopic removals from 19% to 7% without raising pancreatitis risk.
Upadacitinib, infliximab showed fastest symptom relief in ulcerative colitis, analysis found
-
by Meg Barbor
A post hoc analysis suggests onset of action may help guide advanced therapy selection in moderate to severe ulcerative colitis.
Dupilumab cuts stomach eosinophils in eosinophilic gastritis trial
-
by Doug Brunk
Phase 2 trial found reductions in gastric eosinophils and endoscopic disease activity, although symptom scores did not significantly improve after 12 weeks.
GLP-1 receptor agonists not tied to higher overall pancreatitis risk, study finds
-
by Matthew Solan
A target trial emulation found GLP-1 receptor agonists carry an early drug-induced risk offset by later reductions in alcohol and hypertriglyceridemia-related pancreatitis.
